The effect of duloxetine on urethral sphincter morphology

Duckett, Jonathan; Patil, A.; Aggarwal, Ieera Madan

doi:10.1002/uog.5202

Cited by 8 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the intervention, sphincter thickness and area measurements were similar to those found in continent women by both Morgan et al and Preyer et al [8,27]. The increases in thickness are also similar in magnitude to those reported by Athanasiou et al and Duckett et al in studies of the effects of duloxetine [28,29]. These increases in sphincter size appear to be clinically relevant; thickness and cross-sectional area both increased by ∼20 %, which is well above the estimated mean percent error of 12-15 %.…”

Section: Discussionsupporting

confidence: 84%

Changes in urethral sphincter size following rehabilitation in older women with stress urinary incontinence

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 84%

Changes in urethral sphincter size following rehabilitation in older women with stress urinary incontinence

et al. 2014

View full text Add to dashboard Cite

show abstract

“…24 A sub-analysis of women who had a symptomatic improvement with duloxetine revealed these increases to be even more marked. Another ultrasound study has confi rmed that duloxetine leads to a signifi cant increase in the width of the smooth muscle component of the urethral sphincter, with no corresponding increase in urethral length, 25 which raises the interesting prospect that duloxetine leads to enhanced activity of smooth as well as striated muscle. The available evidence would seem to support the conclusion that duloxetine improves the symptom of SUI by increasing urethral closure pressure and potentiating the electrical activity of the sphincter.…”

Section: Effect Of Duloxetine On the Lower Urinary Tractmentioning

confidence: 99%

Update on duloxetine for the management of stress urinary incontinence

Basu¹,

Duckett²

2008

CIA

View full text Add to dashboard Cite

Duloxetine is a relatively balanced serotonin and noradrenaline reuptake inhibitor (SNRI), which is the fi rst drug with widely proven effi cacy to have been licensed for the medical treatment of women with stress urinary incontinence (SUI). Despite favorable results from randomized controlled trials, surgical management continues to be the mainstay of treatment for SUI. In this review we explore the pharmacology of duloxetine in the nervous system and lower urinary tract, and the evidence for its use in the management of women with urinary incontinence.

show abstract

“…The on/off mechanism and theory of glutamate sounds plausible but is not backed up by clinical studies. Although there should only be striated muscle effects, ultrasound studies suggest a smooth muscle-mediated action of duloxetine [19]. Although the on/off mechanism of action should not result in any changes in voiding, one study describes worse outcomes if voiding is already compromised before the start of therapy [20].…”

mentioning

confidence: 99%